Fisher Alexander A, Davis Michael, Jeffery Ian
Department of Geriatric Medicine, The Canberra Hospital, The Canberra Clinical School of the University of Sydney, Canberra, Australia.
Cardiovasc Drugs Ther. 2002 Mar;16(2):161-5. doi: 10.1023/a:1015761618314.
To describe a case of delirium associated with use of metoprolol and to analyse 24 such cases including 22 cases reported to Australian Adverse Drug Reaction Advisory Committee and one case previously published (S. Ahmad, Am Fam Physician, 1991;44:1142, 1144).
An 89 year old caucasian man with an acute coronary syndrome who had no psychiatric history and no infections, brain injury, stroke, metabolic nor neoplastic disease developed delirium after two small doses of metoprolol (25 mg). The delirium disappeared within 20 hours after metoprolol was ceased, despite continuing all other medications. THE COMBINED SERIES: Of 24 patients (12 women, mean age 71.8 years), 83% were older than 60 years. The duration of therapy before onset of delirium in 14 (58%) subjects was within one week; 23 of 24 patients were receiving therapeutic amounts of the drug (25-200 mg/day). Clinical features included confusion/disorientation in all subjects, agitation in 13, aggression in 6, visual hallucinations in 7, auditory hallucinations in 1, paranoid delusions in 3, vivid dreams in 2 and language disturbances in 3 persons. Bradycardia was reported in 4 cases, hypotension in 2, fatigue/tiredness in 3, Raynaud's phenomenon in 1 and skin rash in 1 patient.
The mechanism of metoprolol-induced delirium is unclear. It could be due to impairment of hepatic metabolism (especially in the ageing liver) and complex neurotransmitter-related effects on brain beta-adrenoceptors and serotonin (5-HT) receptors.
Physicians should be aware that metoprolol, a widely used beta-blocker, may rarely cause delirium, especially in the elderly population.
描述一例与使用美托洛尔相关的谵妄病例,并分析24例此类病例,其中包括向澳大利亚药物不良反应咨询委员会报告的22例以及之前发表的1例(S. 艾哈迈德,《美国家庭医生》,1991年;44:1142, 1144)。
一名89岁的白种男性,患有急性冠状动脉综合征,无精神病史,无感染、脑损伤、中风、代谢性疾病及肿瘤性疾病,在服用两小剂量美托洛尔(25毫克)后出现谵妄。尽管继续使用所有其他药物,但在停用美托洛尔后20小时内谵妄消失。
24例患者(12名女性,平均年龄71.8岁)中,83%年龄超过60岁。14例(58%)受试者在谵妄发作前的治疗时间在一周内;24例患者中有23例接受了治疗剂量的药物(25 - 200毫克/天)。临床特征包括所有受试者均有混乱/定向障碍,13例有激动,6例有攻击行为,7例有视幻觉,1例有听幻觉,3例有偏执妄想,2例有生动梦境,3例有语言障碍。4例报告有心动过缓,2例有低血压,3例有疲劳/疲倦,1例有雷诺现象,1例有皮疹。
美托洛尔所致谵妄的机制尚不清楚。可能是由于肝脏代谢受损(尤其是在老年肝脏中)以及对脑β - 肾上腺素能受体和5 - 羟色胺(5 - HT)受体复杂的神经递质相关作用。
医生应意识到,广泛使用的β受体阻滞剂美托洛尔可能很少引起谵妄,尤其是在老年人群中。